Metrosa

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Metrosa

Metrosa is a trade name for medications containing the active substance Metronidazole, a compound recognized globally as a critical and foundational antimicrobial agent.

Property Description
Active ingredient Metronidazole (INN)
Form Oral (tablet, capsule), Topical (gel, cream), or Intravenous (infusion)
Pharmacological class Nitroimidazole Antimicrobial
Common purpose To eliminate specific anaerobic bacteria and protozoa
Origin Synthetic (chemically manufactured)

The Definition and Class of Metronidazole

Metrosa is a medication containing the active substance Metronidazole, which is precisely classified as a Nitroimidazole antimicrobial agent. This compound is entirely synthetic, positioning it as a medicine with a distinct dual activity: it serves both as an antibiotic against specific anaerobic bacteria and an antiprotozoal medication against certain parasites.

This agent's unique mechanism is clinically recognized for its selective toxicity, which ensures the drug primarily targets harmful microorganisms that thrive in low-oxygen environments. Metronidazole is recognized as an essential medicine for addressing a range of infections globally.

Composition and Available Forms

The therapeutic core of Metrosa preparations is Metronidazole (C6H9N3O3), typically presented as a single active ingredient product. The consistency assured by its synthetic origin is a key feature of its production.

To facilitate targeted use, the medication is available in a versatile range of dosage form(s). These include oral preparations such as tablets and capsules, which are intended for systemic circulation, and topical preparations, like gels and creams, compounded for local application. Additionally, sterile solutions for intravenous infusion are available for when rapid or intensive therapy is required, providing comprehensive delivery options.

The General Purpose of This Antimicrobial Agent

The general purpose of Metronidazole is to resolve and prevent infections caused by susceptible anaerobic bacteria and protozoa. The drug functions as a prodrug that, once activated inside the microbe, disrupts its essential genetic material, leading to the necessary microbicidal effect. Beyond its systemic role in addressing infectious agents, the use of topical forms also offers the general therapeutic benefit of reducing inflammation and redness associated with chronic skin lesions.

What side effects are possible with Metrosa?

Possible Side Effects and Safety Information

Metrosa's safety profile, based on regulatory documentation, involves localized reactions as well as systemic risks related to its chemical class (nitroimidazole).

Commonly Reported Adverse Reactions

Side effects observed in clinical trials with topical formulations, occurring with an incidence greater than 2%, primarily include nasopharyngitis (sore throat and nasal congestion), upper respiratory tract infection, and headache. Local cutaneous reactions frequently reported include stinging/burning, dryness, erythema (redness), and pruritus (itching).

Serious and Clinically Significant Risks

  • Neurologic Effects: Cases of peripheral neuropathy (characterized by numbness or paresthesia of an extremity) have been reported with both systemic and post-approval topical use. The appearance of abnormal neurologic signs requires prompt reevaluation of therapy.
  • Blood Dyscrasias: Metrosa should be used with caution in patients with a history of blood dyscrasia due to its classification as a nitroimidazole.
  • Carcinogenic Potential: Based on animal studies in mice and rats involving chronic oral administration, metronidazole has shown evidence of carcinogenic activity. This information is included in official warnings.

Specific Safety Precautions and Restrictions

Metrosa is contraindicated in individuals with a known hypersensitivity to metronidazole or any other component in its formulation. Patients with pre-existing Central Nervous System (CNS) diseases or a history of blood dyscrasia should use the medication with caution. Avoid contact with the eyes, as topical application has been reported to cause tearing and irritation. If symptoms of contact dermatitis (irritant or allergic) develop, discontinuation of use may be necessary.

Population-Specific Considerations

Metrosa is known to cross the placental barrier. Use during pregnancy is generally advised only if clearly necessary. Breastfeeding is not recommended during treatment due to the potential for serious adverse reactions in the infant following oral administration.

Overdose and Emergency Response

Official Regulatory Information for Metrosa Overdose

Regulatory documentation defines Metrosa (metronidazole) overdose based on the following officially cataloged symptoms and mandated emergency actions. Overexposure has been reported following accidental and intentional single oral doses.

Overdose Feature Documented Regulatory Statement
Documented Manifestations Manifestations reported in cases of high exposure include nausea, vomiting, and ataxia (impairment of coordination).
Severe Outcomes The potential for severe neurological effects, specifically seizures and peripheral neuropathy, is documented following high-dose or prolonged regimens.
Critical Population Risk A distinct, life-threatening risk of acute hepatic failure with a very rapid onset is officially noted for patients with Cockayne syndrome who receive systemic metronidazole.
Antidote Status Official regulatory statements confirm that no specific antidote is known for Metrosa overdose.

Mandated Emergency Intervention and Management

The official prescribing information requires that patients seek immediate medical attention or contact a poison control center for suspected overexposure. If severe, life-threatening symptoms such as collapse, difficulty breathing, or seizure occur, emergency services must be called immediately. Management of overdosage is restricted to symptomatic and supportive therapy. Furthermore, the drug must be discontinued immediately upon the development of any abnormal neurological signs to mitigate potential further effects.

Therapeutic Uses of Metrosa

What Metrosa Treats: Main Uses and Benefits

Metrosa is commonly used across conditions presenting with acute or disruptive episodes, helping to address symptom clusters that may become intense or disruptive. The medication is applied across domains where additional symptomatic support is needed, primarily relevant in contexts involving infectious agents such as specific anaerobic bacteria and protozoa.

It is considered relevant for managing infections of the gynecological and gastrointestinal systems, including Bacterial Vaginosis, Trichomoniasis, Amebiasis, and Giardiasis. It is also commonly used to help with managing symptoms related to inflammatory states associated with mouth and dental infections. In the chronic domain, the topical form may be part of symptomatic management for Rosacea.

In all these scenarios, the medication contributes to easing the overall symptom load, which supports the patient during difficult episodes by easing distress.

“Metrosa is applied in scenarios where additional management of discomfort is required, helping to maintain a sense of stability when symptoms are more noticeable.”


Quick Fact: Support for Acute Symptomatic Discomfort Metrosa is considered relevant when short-term symptomatic assistance is needed for severe infectious symptoms like fever and localized pain linked to deep anaerobic infections.

Eligibility and Restrictions for Use

This information details the officially documented constraints and exclusions for using Metrosa (metronidazole), based strictly on authoritative governmental regulatory documents.

Populations That Must Not Use Metrosa (Contraindications)

Metrosa is contraindicated in patients with a documented history of hypersensitivity or allergic reaction to metronidazole or any other nitroimidazole derivative. It is also prohibited for patients who have taken the drug Disulfiram within the last two weeks, or for patients who consume alcohol or propylene glycol-containing products during therapy and for at least three days after the final dose. Specific systemic formulations are contraindicated in patients diagnosed with Cockayne syndrome due to the risk of severe hepatotoxicity.

Populations Requiring Caution or Restriction

  • Hepatic Impairment: Patients with severe liver disease (Child-Pugh C) require a 50% dose reduction for systemic use, while patients with milder impairment should be closely monitored.
  • Pregnancy: Systemic use is generally advised against during the first trimester of pregnancy. For other trimesters, use is reserved only if the benefits clearly outweigh the potential risks.
  • Lactation: Metronidazole is secreted into breast milk; official labeling suggests a decision be made to either discontinue nursing or discontinue the drug.
  • Age: Safety and effectiveness are not established for most indications in the pediatric population. Geriatric patients should be monitored closely due to a higher potential for adverse events.

What should I know about interactions with other medicines?

Metrosa has officially documented interactions, primarily categorized as absolute prohibitions and systemic exposure modifications. Co-administration of Metrosa with Disulfiram is a formal regulatory prohibition due to the risk of psychotic reactions, requiring separation of at least two weeks (14 days) prior to starting therapy. Similarly, use with alcoholic beverages and products containing propylene glycol is a contraindication, associated with a disulfiram-like reaction; avoidance is required during therapy and for a minimum of three days (72 hours) following the final dose.

Metrosa significantly impacts the systemic exposure of several co-administered medicines. It is documented to potentiate the anticoagulant effect of Warfarin, necessitating close monitoring of prothrombin time. It is also shown to increase serum concentrations of agents such as Lithium and Busulfan, which can lead to potential toxicity. Cimetidine increases Metrosa's own plasma concentration by reducing its clearance. Conversely, Metrosa may decrease the systemic exposure of Mycophenolate.

A pharmacodynamic interaction exists with other QT-prolonging drugs, posing an additive risk of QT prolongation. In specific populations, pharmacokinetic alterations are noted: patients with Severe Hepatic Impairment exhibit slower metabolism, leading to Metrosa accumulation in the plasma. Those with End-Stage Renal Disease show significant accumulation of metabolites.

Mechanism of Action

How Metrosa Works

Metronidazole, the active substance in Metrosa, operates through two distinct, fundamental mechanistic domains: a specific, reduction-dependent microbicidal action and a separate, local anti-inflammatory effect. The drug is a prodrug, meaning it requires activation by the target organism to become cytotoxic, reflecting its dependence on anaerobic conditions for activation.


Chemically Selective Targeting of Pathogen DNA

The primary mechanism is contingent upon the unique, low-oxygen (hypoxic) metabolism found in susceptible anaerobic microbes. The drug is taken up and enzymatically reduced by microbial nitroreductase enzymes and ferredoxin to form a highly reactive cytotoxic nitroradical intermediate. This unstable free radical immediately binds to and fragments the microbe's DNA and other essential macromolecules, a process that rapidly halts all replication and function. This specialized activation mechanism dictates the drug's specificity, resulting in the elimination of susceptible pathogens.


Modulation of Local Inflammatory Mediators

Beyond its role as a microbicidal agent, Metronidazole also engages a separate, non-antimicrobial mechanism relevant to localized applications. This involves the drug acting as a potent scavenger of Reactive Oxygen Species (ROS) and modulating localized immune processes, such as the signaling pathways that drive neutrophil activity in the tissue. This modulation of the inflammatory cascade results in the modulation of localized immune signaling, producing the physiological effect of decreased local tissue vasodilation and edema.

Dosage and Administration Information

How to Use Metrosa

Metrosa, containing the active substance metronidazole, is administered via oral, intravenous (IV), and topical/vaginal routes, depending on the required therapeutic approach and formulation. The medicine is available in several forms, including immediate-release tablets, extended-release tablets, capsules, oral suspension, and a solution for IV infusion.


Dosing and Administration Schedules

Administration patterns are standardized. For anaerobic infections, a 15 mg/kg IV loading dose is often followed by 7.5 mg/kg maintenance dosing, with a typical treatment duration of 7 to 10 days. Oral regimens vary; for instance, 500 mg tablets are often prescribed twice daily (BID) or three times daily (TID) for certain parasitic and bacterial infections. Extended-release tablets, when used, are typically administered once daily (OD).


Administration Conditions and Adjustments

Specific instructions govern oral intake: Immediate-release forms may be taken with food, while extended-release tablets must be taken on an empty stomach, meaning 1 hour before or 2 hours after a meal. These tablets must be swallowed whole and are not to be crushed or chewed. Intravenous infusions require slow administration over 30 to 60 minutes.

Usage protocols include population-specific rules, notably a 50% dosage reduction indicated for patients diagnosed with severe hepatic impairment. Furthermore, while routine dosage adjustments are not typically required for patients with renal failure, the timing of administration for patients on hemodialysis follows the clinical practice of re-administering the dose immediately after the dialysis procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Metrosa (Metronidazole)

This summary outlines what researchers have studied about Metrosa, the types of outcomes they measured, and what remains unclear, using language intended to be neutral and patient-friendly. Findings describe group patterns observed in the studies and do not provide individual predictions or clinical advice.


Evidence for Systemic Anaerobic Bacterial Infections and Status

Metrosa was studied for its use in treating severe infections caused by anaerobic bacteria. These trials often used comparative study designs, where Metrosa was observed in a combination regimen. Researchers monitored outcomes related to systemic or functional imbalance, such as the monitoring of changes in the signs and symptoms of infection, and the rate of bacteriological clearance, which measures the elimination of the targeted organisms. Research highlights changes measured during the study period that provided data on the status of bacterial infection clearance. A key limitation is that Metrosa is typically studied as part of a combination of drugs, making the effect of Metrosa alone difficult to precisely isolate.


Studies for Protozoal Infections: Trichomoniasis, Amebiasis, and Giardiasis

Metrosa was evaluated in studies focused on common protozoal infections—conditions associated with acute or disruptive episodes. Studies used Randomized Controlled Trials and comparison trials to measure key outcomes, primarily the rate of parasitic clearance and outcomes related to physical discomfort. Comparative studies describe patterns in the recurrence of infection when assessing multi-day regimens versus single-dose treatments. Studies consistently describe the challenge of the infection recurring shortly after initial clearance, and research was studied for patterns of microbial resistance in some protozoa.


Research on Topical Metrosa for Inflammatory Skin Conditions (Rosacea)

Topical Metrosa was studied for Rosacea, a condition characterized by fluctuating or episodic manifestations. Trials used Randomized, Vehicle-Controlled Designs on adult populations. Researchers primarily measured outcomes linked to inflammatory or irritative states, focusing on the measurements of inflammatory lesions (papules and pustules) and changes in facial redness. While findings indicate patterns related to inflammatory lesions, the evidence for the impact on general background facial redness (erythema) alone is described as limited and heterogeneous. Furthermore, there is limited information for long-term outcomes regarding continuous use over many years across all indications.

Frequently Asked Questions (FAQ)

Common questions about Metrosa (FAQ)

Q: Are there different strengths of Metrosa tablets available?

Yes, the medicine is available in various oral dosage forms. These include immediate-release tablets in different strengths, such as 250 mg and 500 mg, as well as a 750 mg extended-release tablet.

Q: What does the term 'contraindication' mean for Metrosa?

In regulatory documents, a contraindication refers to a condition or factor that strictly prohibits the use of the medicine because the risks of taking it would outweigh any possible benefit. Examples include having a known allergy to the drug's components or having recently taken certain other medications, like Disulfiram.

Q: Is Metrosa associated with any specific diet restrictions?

Official product information dictates the complete prohibition of alcoholic beverages and products containing propylene glycol throughout the duration of therapy and for a minimum of three days following the final dose. This is because the combination can lead to a disulfiram-like reaction.

Q: Why does Metrosa need to be taken consistently?

Official patient information warns about the importance of consistency. Skipping doses could result in the infection not being completely treated, which could also increase the possibility of bacteria becoming resistant to the medicine.

Q: What happens if a dose of Metrosa is forgotten?

Official patient information generally advises that if a dose is forgotten, the instruction is to take it as soon as possible. However, if it is almost time for the next scheduled dose, the guideline is to skip the missed dose. Instructions state a double dose should not be taken to make up for a forgotten one.

Q: How long does it usually take to notice the effects of Metrosa?

The time frame for noticing effects can vary between individuals and conditions. However, official patient information notes that it may take a couple of days to observe changes or improvement in symptoms.

Q: Is Metrosa intended for long-term or short-term use?

Metrosa is typically used for specific, short-term courses of treatment; for example, many anaerobic infections have a standard treatment duration of 7 to 10 days. Research summaries note that there is limited information available concerning the long-term outcomes of continuous use over many years.

Q: Is Metrosa commonly used by older adults?

Studies reviewed by regulatory bodies include information on how the medicine is processed in older adults (geriatric patients), indicating its use in this population. However, official information notes that close monitoring may be necessary for patients in this age group due to the potential for adverse events.

Q: Does taking Metrosa affect the ability to drive or operate machinery?

Regulatory warnings include the risk of certain Central Nervous System (CNS) effects, such as encephalopathy and convulsive seizures. These types of effects may potentially impact physical and mental abilities. Regulatory materials note that caution should be exercised when operating machinery or driving.

Q: Do researchers know exactly how Metrosa produces its described effects?

Official documentation describes the drug's action in detail, noting two distinct ways it works: selective microbicidal (killing organisms) and anti-inflammatory action. While these effects are known, some official sources indicate that the precise mechanism of action is not entirely clear to researchers.

Q: What is the safety classification of Metrosa by the FDA/EMA?

The FDA classifies the active substance in Metrosa as Pregnancy Category B. This classification means that, based on studies in animals, there was no evidence of harm to the fetus. However, studies conducted in pregnant women are limited.

Q: What is the common experience regarding changes in mood while on Metrosa?

The drug is associated with certain neuropsychiatric effects. Serious adverse reaction reports have included instances of confusion, psychosis, and changes in mood. These reported changes in mood have involved symptoms such as depression or mania.

Q: I've heard Metrosa can cause unusual dreams; is that listed as a known side effect?

The drug is associated with potential neurologic effects. Official documents report clinically significant neurologic effects, such as peripheral neuropathy, confusion, and psychosis. Broader medical literature mentions that certain neuropsychiatric symptoms, like bad dreams, can be part of this reported experience.

Q: What should be done if an adverse reaction is suspected?

Official warnings state that if serious abnormal signs develop, the risk/benefit of continuing therapy should be professionally reevaluated. Guidance is provided to report any suspected adverse reaction to a healthcare professional.

Q: Does Metrosa interact with herbal remedies like St. John's Wort?

Official interaction information advises that Metrosa carries an additive risk of QT prolongation when taken with other drugs that affect heart rhythm. Official guidance stresses the importance of disclosing all herbal supplements to a healthcare professional, as some (like St. John's Wort) can influence heart rhythm.

Q: Does Metrosa interact with common vitamins or supplements?

Official drug interaction information generally focuses on other prescription medications. While the regulatory documents do not typically list specific interactions with common vitamins, official guidance stresses the importance of disclosing all supplements, vitamins, and herbs to a healthcare professional.

Q: Are there any known issues with taking Metrosa before or after surgery?

Regulatory information advises caution for patients with a history of blood dyscrasia. Additionally, Metrosa is known to increase the effect of the anticoagulant Warfarin, which is often used in surgical settings. Close monitoring of blood parameters may be required by the prescribing clinician when these drugs are taken together.

Q: What is the difference between Metrosa and the placebo in clinical trials?

Studies comparing Metrosa to a placebo or a vehicle (a substance without the active drug) focused on measuring specific outcomes. Researchers looked for changes in the signs and symptoms of infection, the rate at which the targeted organisms were cleared, and measurements of inflammatory lesions in localized applications.

Q: Is it necessary to take Metrosa at a specific time of day?

Official administration guidelines prescribe the total number of doses per day (such as once daily or three times daily). Some official patient information suggests that taking the doses with consistency can help maintain a uniform amount of the medicine in the body.

Q: Is it true that Metrosa requires regular blood tests?

Official prescribing information indicates that patients with certain pre-existing conditions, such as severe liver or kidney disease, are noted in regulatory information as needing close monitoring. For these and other reasons, laboratory tests, including blood tests, may be ordered to monitor a patient’s overall response to the medicine.

Q: Is Metrosa considered a controlled substance?

No. Official regulatory labeling in the United States indicates that Metrosa's active substance is not listed on the DEA Controlled Substance Schedule.

Q: Does Metrosa have a generic version available?

Yes. The active substance metronidazole is generally available in generic versions, which is noted in regulatory product labeling. This includes Authorized Generic status for various formulations of the medicine.

How should Metrosa be stored and disposed of?

How to Store and Dispose of Metrosa (Metronidazole)

Metrosa must be stored under specific conditions defined in its official regulatory labeling to ensure product stability and maintain public safety.

Storage Requirements

Formulation Temperature & Protection Handling Constraints
Oral (Tablets/Capsules) Store at Controlled Room Temperature (20 C to 25 C) and protect from light. Must be stored in a tight, light-resistant container with a child-resistant closure.
Intravenous (IV) Store at Controlled Room Temperature (20 C to 25 C) and protect from light until use. Do not refrigerate (risk of precipitation) or add components to the solution bag.

All forms must be stored out of the sight and reach of children.

Disposal

Metrosa should not be flushed down the toilet. Unused or expired medication must be disposed of via an authorized drug take-back program or, if unavailable, through the FDA-recommended household trash procedure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Metrosa found in:

A-Z Index: